Gri Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

30 Jan 2026

GRI

10-K: GRI Bio Reports Positive Phase 2a IPF Data, Faces Going Concern

GRI Bio, Inc. announced positive topline results from its Phase 2a clinical trial for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), while also disclosing substantial doubt about its ability to continue as a going concern.

NASDAQ

14 Mar 2025

GRI

Gri Bio, INC

10-K: GRI Bio Reports 2024 Financial Results and Provides Business Update

GRI Bio, a clinical-stage biopharmaceutical company, details its financial performance for 2024 and outlines key developments in its pipeline, including its lead candidate GRI-0621 for IPF.

NASDAQ

28 Mar 2024

GRI

Gri Bio, INC

10-K: GRI Bio, Inc. Files 10-K Report, Outlines Clinical Progress and Financial Position

GRI Bio, Inc. released its 10-K filing, detailing clinical trial advancements for GRI-0621 and GRI-0803, alongside its financial status and future funding needs.